Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study
Sponsor: Ipsen
Terminated
Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day
Other terminated trials from Ipsen
Other Growth Disorders trials with similar outcome
Listed as NCT00330668, this PHASE3 trial focuses on Growth Disorders and remains terminated or withdrawn. Sponsored by Ipsen, it has been updated 9 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Aug 2020 — Sep 2020 [monthly]
Terminated PHASE3
-
Jun 2018 — Aug 2020 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .